Daniel O’Connor has resigned from his positions as CEO, president, and board member of Princeton, NJ-based Advaxis (NASDAQ: [[ticker:ADXS]]). No reason for O’Connor’s resignation was given in a company news release or documents filed with securities regulators. O’Connor had served as CEO of Advaxis, a cancer immunotherapy developer, since 2013. Advaxis chief business officer Anthony Lombardo is now serving as interim CEO.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
